Business Context and Reporting Period
Company: Corcept Therapeutics Incorporated (CORT)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2024
Business Overview: Corcept is a commercial-stage pharmaceutical company focused on treating severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating cortisol. Its primary commercial product is Korlym (mifepristone) for Cushing's syndrome. In June 2024, the company launched an authorized generic version of Korlym. The company is also advancing a pipeline of selective cortisol modulators, including relacorilant (Cushing's syndrome, ovarian cancer), dazucorilant (ALS), and miricorilant (MASH).
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Product Revenue, Net | $182,546 | $123,601 | $493,150 | $346,970 |
| Cost of Sales | $2,867 | $1,645 | $7,926 | $4,604 |
| Gross Margin % | 98.4% | 98.7% | 98.4% | 98.7% |
| Operating Expenses | $135,948 | $92,424 | $381,461 | $271,357 |
| Income from Operations | $46,598 | $31,177 | $111,689 | $75,613 |
| Net Income | $47,213 | $31,378 | $110,463 | $74,785 |
| Diluted EPS | $0.41 | $0.28 | $0.98 | $0.66 |
| Cash & Cash Equivalents | $137,289 | $111,800 | $137,289 | $111,800 |
| Total Marketable Securities | $410,357 | $289,846 | $410,357 | $289,846 |
| Total Liquidity (Cash + Securities) | $547,646 | $401,646 | $547,646 | $401,646 |
Note: Liquidity figures represent the sum of Cash and Cash Equivalents plus Short-term and Long-term Marketable Securities as of the period end.
Material Changes vs. Prior Period
- Revenue Growth: Net product revenue increased 47.7% year-over-year in Q3 2024 ($182.5M vs. $123.6M) and 42.1% for the nine-month period ($493.2M vs. $347.0M). Growth was driven primarily by higher sales volumes (89% of Q3 increase) and a price increase effective January 1, 2024.
- Expense Increases:
- R&D: Increased to $59.3M in Q3 2024 from $45.5M in Q3 2023 due to advancement of clinical programs (Oncology, Cushing's, Metabolic) and higher compensation.
- SG&A: Increased to $73.7M in Q3 2024 from $45.3M in Q3 2023, driven by increased employee compensation and sales/marketing activities.
- Profitability: Operating income rose 49.5% in Q3 2024 to $46.6M. Net income increased 50.5% to $47.2M.
- Share Repurchases: The company repurchased 0.3 million shares in Q3 2024 for $11.7M under its $200M stock repurchase program. $184.3M remains available under the program.
- Lease Activity: In April 2024, the company entered a six-year sublease for new headquarters in Redwood City, CA, effective August 1, 2024, resulting in a new right-of-use asset and lease liability.
Guidance, Outlook, Risks, and Contingencies
- Outlook: Management expects R&D and SG&A expenses to be higher in 2024 than 2023 as clinical programs advance and commercial activities expand. The company expects to fund operations for the next 12 months and beyond without raising additional capital.
- Legal Proceedings:
- Teva Patent Litigation: Teva launched a generic version of Korlym in January 2024. A district court ruled in December 2023 that Teva's product does not infringe Corcept's patents; Corcept has appealed this decision to the Federal Circuit. The outcome is uncertain.
- Teva Antitrust Litigation: Teva filed an antitrust complaint in June 2024 alleging unfair business practices. Corcept has moved to dismiss.
- Melucci Litigation: A securities class action settlement was approved in June 2024. The $14M payment was fully reimbursed by insurance.
- Government Investigation: The U.S. Attorney's Office for the District of New Jersey is investigating the sale and promotion of Korlym. Corcept is not currently a defendant but is cooperating.
- Regulatory Risks: The Inflation Reduction Act (IRA) may significantly limit Medicare reimbursement rates and introduce inflation rebates, potentially reducing revenue and profits starting in 2025. Public perception and legislation regarding mifepristone (the active ingredient in Korlym) due to its use in abortion could impact sales.
- Development Pipeline:
- Relacorilant: Phase 3 trials (GRACE, GRADIENT) for Cushing's syndrome are complete with positive results. Phase 3 trial (ROSELLA) for ovarian cancer is complete; data readout is pending.
- Miricorilant: Phase 2b trial (MONARCH) for MASH is ongoing. A Phase 1 trial for antipsychotic-induced weight gain was discontinued in June 2024 due to lack of efficacy.
Investor Verification Checklist
- Generic Competition Impact: Verify the actual revenue impact of Teva's generic Korlym launch and the status of the patent infringement appeal.
- Relacorilant Approval Timeline: Confirm the expected filing date for the New Drug Application (NDA) for relacorilant in Cushing's syndrome following the completion of Phase 3 trials.
- ROSELLA Trial Data: Monitor the release date and results of the Phase 3 ROSELLA trial for relacorilant in ovarian cancer, which is a key value driver.
- IRA Reimbursement Exposure: Assess the specific financial modeling regarding the Inflation Reduction Act's impact on Medicare Part D pricing and rebates for Korlym.
- Legal Settlements: Track the resolution of the Teva antitrust lawsuit and the ongoing government investigation into Korlym marketing practices.